Clinical trials: Amyloid Beta Protein
Alzheimer Disease
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00500500
- Testing
- EGb 761® (Tanakan®)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Ipsen
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Down Syndrome (DS), Down Syndrome (Trisomy 21)
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
- Conditions
- Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Disease, Amyloid Beta Protein
- Trial name
- ALADDIN (NCT06911944)
- Testing
- Donanemab
- Volunteers
- 60 people
- Sponsor
- Michael Rafii, MD, PhD
Hypertension
Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)
The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults.
- Trial name
- HIPAC (NCT03354143)
- Testing
- Standard Care, Intensive Treatment
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Mild Cognitive Impairment
Home-based Cognitive Monitoring in MCI
This study is an observational study to confirm usefulness of a home-based cognitive monitoring in non-demented patients with high-risk of dementia
- Trial name
- NCT04350801
- Testing
- home-based cognitive monitoring
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Normal Physiology
Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People
Background: Brain activity creates waste products. The body s glymphatic system removes this waste, especially during sleep. One brain waste product is amyloid-beta (Ab). It plays a role in Alzheimer s disease.
- Trial name
- NCT02669225
- Testing
- [18F]florbetaben
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Alzheimer's Disease
Genistein as a Possible Treatment for Alzheimer's Disease.
Genistein is an isoflavone that has antioxidant and neuroprotective effects on Alzheimer's disease (AD). A few years ago our group reported that genistein increased PPARg (peroxisome proliferator activated receptor gamma) levels.
- Trial name
- GENIAL (NCT01982578)
- Testing
- Genistein
- Where
- 2 sites in Spain
- Volunteers
- 27 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-388 and MNI 390, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed…
- Trial name
- NCT00886951
- Testing
- I123MNI388/I123MNI390
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Dementia
Triglyceride-rich Lipoprotein and Development of Dementia
Because of the rapid aging of the global population, dementia has become a serious problem, and Alzheimer's disease (AD) is the most common cause of dementia.
- Trial name
- NCT02814422
- Where
- Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Alzheimer's Disease (AD)
Prospective Single-Arm Safety Study of Cervical LVA in AD Patients
Official Title Prospective Single-Arm Safety Study of Cervical Lymphaticovenular Anastomosis (LVA) in Patients with Alzheimer's Disease Purpose of the Study Researchers are conducting this study to see if a minimally invasive…
- Trial name
- Neck LVA (NCT07458620)
- Testing
- Supermicrosurgical Lymphaticovenular Anastomosis (LVA)
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- AV94 (NCT00605059)
- Testing
- [123I]AV94
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
- Trial name
- NCT03522129
- Testing
- CT1812
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cognition Therapeutics
Alzheimer's Disease
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease…
- Trial name
- NCT00299988
- Testing
- Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer Disease
Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics
Introduction: Alzheimer's disease (AD) is characterized by neurodegeneration of the brain in the form of neurofibrillary tangles and plaques containing the amyloid-beta protein (Abeta).
- Trial name
- AWAKE (NCT01194713)
- Testing
- Sleep deprivation
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University Medical Center Nijmegen
Alzheimers Disease
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
The underlying goal of this study is to assess 123-I MNI-187 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00456417
- Testing
- 123-I MNI-187 Injection and Imaging Procedures
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Elderly Individuals Aged 60 Years or Older, Mild Cognitive Impairment (MCI)
THE EFFECTS OF GAMBIR CATECHIN (UNCARIA GAMBIR ROXB) SUPPLEMENTATION ON COGNITIVE FUNCTION, EXPRESSION OF APP, MAPT, BDNF, IL-10, TGF-Β GENES, AND PLASMA MDA LEVELS IN THE ELDERLY.
Objective The primary objective of this clinical trial is to investigate the effects of gambir catechin administration on cognitive function, the expression of amyloid precursor protein (APP), microtubule-associated protein tau…
- Trial name
- NCT06604390
- Testing
- catechin extracts (health food), plasebo
- Where
- 2 sites in Fiji, Indonesia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Rahmi Novita Yusuf